Sector News

Perrigo spurns second offer from Mylan

April 27, 2015
Life sciences
The Perrigo-Mylan-Teva takeover saga has taken another turn after Perrigo again spurned Mylan’s advances, rejecting a second bid from the generics giant.
Desperate to protect itself from a Teva takover, Mylan has laid a new bid on the table for Perrigo of $60 cash and 2.2 of its share’s for every remaining share in the Dublin, Ireland-based firm. This, it claims, values the deal at around $222 per Perrigo share.
However, Perrigo has taken a different stance on Mylan’s new proposal, arguing that, based in its own calculations, which uses Mylan’s lower share price before rumours of Teva’s interest started to grow, the offer actually only equates to $188 a share.
This, it notes, falls under the $205 a share proposed by Mylan early last week. As such, Perrigo’s Board “strongly advised” the firm’s shareholders “to take no action in relation to the offer”.
Mylan is yet to respond to Teva’s $40-billion takeover bid, but indications are that it seems reluctant to accept.
By Selina McKee
Source: Pharma Times

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]